

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

RESULTS ESTIMATE OF CR BOYA BIO-PHARMACEUTICAL FOR THE YEAR ENDED 31 DECEMBER 2024

On 22 January 2025, CR Boya Bio-pharmaceutical released its results estimate for the year ended 31 December 2024.

China Resources Boya Bio-pharmaceutical Group Company Limited (華潤博雅生物製藥集團股份有限公司) (“**CR Boya Bio-pharmaceutical**”) is a company incorporated in the People’s Republic of China. The shares of CR Boya Bio-pharmaceutical are listed on the Shenzhen Stock Exchange. As of the date of this announcement, China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) indirectly holds approximately 30.28% of the total share capital and approximately 41.59% voting rights in the total share capital of CR Boya Bio-pharmaceutical, and therefore, CR Boya Bio-pharmaceutical is a subsidiary of the Company.

On 22 January 2025, CR Boya Bio-pharmaceutical released its results estimate for the year ended 31 December 2024, in which, it announced that the net profit attributable to the shareholders of CR Boya Bio-pharmaceutical for the year ended 31 December 2024 is estimated to range from approximately RMB380.00 million to RMB480.00 million (as compared to the same period last year of net profit of approximately RMB237.46 million), net profit attributable to the shareholders of CR Boya Bio-pharmaceutical excluding non-recurring gain or loss is estimated to range from approximately RMB283.74 million to RMB383.74 million (as compared to the same period last year of net profit of approximately RMB143.07 million), and basic earnings per share is estimated to range from approximately RMB0.75 per share to approximately RMB0.95 per share (as compared to the same period last year of profit per share of approximately RMB0.47 per share) (the “**CR Boya Bio-pharmaceutical Results Estimate**”).

The main reasons for the change in CR Boya Bio-pharmaceutical's performance in 2024 as compared with the same period last year are that (i) the increase in revenue from blood products of CR Boya Bio-pharmaceutical in 2024 and the impact of goodwill and asset impairment provision resulting in a lower year-on-year comparative figure in 2023; (ii) the plasma collection volume of 522.04 tonnes achieved by CR Boya Bio-pharmaceutical in its operating plasma stations (16 stations, excluding four operating stations of Green Cross (China) Biopharmaceutical Co., Ltd. (綠十字(中國)生物製品有限公司)), representing a year-on-year increase of 11.71%; and (iii) during the reporting period from 1 January 2024 to 31 December 2024, the impact of non-recurring gains and losses on net profit of CR Boya Bio-pharmaceutical is estimated to be approximately RMB96.26 million.

The CR Boya Bio-pharmaceutical Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. For details of the financial data, those to be disclosed in the annual report for the year ended 31 December 2024 to be issued by CR Boya Bio-pharmaceutical shall prevail.

The financial information in this announcement is limited to CR Boya Bio-pharmaceutical only and does not represent or provide a complete view of the operational or financial status of the Group.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 22 January 2025

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors; and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.